Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients
Authors:
- Sylvia HaasSHSylvia Haas
- Helmut WolfHWHelmut Wolf
- Albrecht EnckeAEAlbrecht Encke
- Ajay K. KakkarAKAjay K. Kakkar
- 1 January 2005
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 94 (10) , 867-871
Abstract
Summary: Cancer patients undergoing surgery are at a high risk of venous thromboembolism, but few studies have described the rate of autopsy-confirmed fatal pulmonary embolism after heparin thromboprophylaxis. In a post hoc analysis of a randomized study (MC-4), which compared the efficacy and safety of certoparin (3000 anti-Xa IU, subcutaneously, once-daily) with unfractionated heparin (5000 IU, subcutaneously, three-times daily) in 23078 patients undergoing surgery lasting more than 30 min, the incidence of autopsy-confirmed fatal pulmonary embolism, death and bleeding in the cancer patients (n=6124) was compared with non-cancer patients (n=16954). Fatal pulmonary embolism was significantly more frequent in cancer patients (0.33% [20/6124]) than in non-cancer patients (0.09% [15/16954], relative risk (RR), 3.7 [95% confidence intervals (CI), 1.80, 7.77], p=0.0001) at 14 days post-prophylaxis. Perioperative mortality was also significantly higher in cancer patients than in noncancer patients (3.14% [192/6124] vs. 0.71% [120/16954], RR, 4.54 [95% CI, 3.59, 5.76], p=0.0001), as were blood loss (p<0.0001), and transfusion requirements (p<0.0001). Prevention of venous thromboembolism in cancer surgical patients remains a clinical challenge.Keywords
Funding Information
- Novartis Pharma GmbH
This publication has 16 references indexed in Scilit:
- Management of thrombosis in cancer: primary prevention and secondary prophylaxisBritish Journal of Haematology, 2005
- Prevention of fatal pulmonary embolism and mortality in surgical patientsThrombosis and Haemostasis, 2005
- The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinomaCancer, 2004
- Pathophysiology of the Thrombophilic State in the Cancer PatientSeminars in Thrombosis and Hemostasis, 1999
- The Thrombophilic State Induced by Therapeutic Agents in the Cancer PatientSeminars in Thrombosis and Hemostasis, 1999
- Prevention of Venous Thromboembolism in Cancer PatientsSeminars in Thrombosis and Hemostasis, 1999
- Efficacy and safety of enoxaparinversus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessmentBritish Journal of Surgery, 1997
- Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patientsBritish Journal of Surgery, 1995
- Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous HeparinNew England Journal of Medicine, 1988
- TUMORS, MUCUS PRODUCTION, AND HYPERCOAGULABILITYAnnals of the New York Academy of Sciences, 1974